Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
2.8
Journals
Healthcare
Special Issues
Urological Cancer Care—Improving Patient Outcomes
share announcement

Urological Cancer Care—Improving Patient Outcomes

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Nursing".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 3970

Special Issue Editor

Dr. Sung-Lang Chen

E-Mail Website
Guest Editor
Department of Urology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
Interests: prognosis; cancer diagnostics; medical oncology; urological cancers; cancer care; prostate cancer; bladder cancer; renal cell carcinoma

Special Issue Information

Dear Colleagues,

This Special Issue aims to collect research works highlighting the meaning of “Urological Cancer Care—Improving Patients’ Outcomes”. There is increasing evidence that surgery and medication in urological cancer treatment have rapidly progressed in recent years. New technology plus target and immunotherapy have ushered in a new era for urological cancer treatment. However, the urological cancer care system has not kept pace with that progress. One-size-fits-all approaches to patient care are rarely successful, particularly when it comes to cancer treatment. Cancer care is strongly associated with cancer outcomes. As such, patients with urological cancers should be managed by a multidisciplinary and collaborative urological cancer care team to keep up with current management steps.

Specific themes we would like to address include but are not limited to the following list:

  • Post-operation care;
  • Urological cancer patient centered care;
  • Supportive and palliative care;
  • Collaborative care system;
  • Model systems for personalized medicine in urological cancer care.

Dr. Sung-Lang Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urological cancers
  • cancer care
  • multidisciplinary
  • prostate cancer
  • bladder cancer
  • renal cell carcinoma

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 252 KiB  
Article
Comprehensive Evaluation of Quality of Life in Penile Cancer Patients following Surgical Treatment
by Darko Jovanović, Miodrag Aćimović, Tomislav Pejčić, Bogomir Milojević, Bojan Čegar, Milica Zeković, Nikola Lisičić, Zoran Džamić and Gorica Marić
Healthcare 2023, 11(23), 3091; https://doi.org/10.3390/healthcare11233091 - 04 Dec 2023
Viewed by 916
Abstract
Background: Penile cancer (PC) is a highly aggressive disease, with a significant tendency for lymphatic spreading and subsequent development of distant metastases. The mutilating nature of PC surgical treatment has profound implications on the patient’s body integrity and self-image, sexual life and intimacy, [...] Read more.
Background: Penile cancer (PC) is a highly aggressive disease, with a significant tendency for lymphatic spreading and subsequent development of distant metastases. The mutilating nature of PC surgical treatment has profound implications on the patient’s body integrity and self-image, sexual life and intimacy, voiding and mental health. The aim of our study was to comprehensively evaluate PC patients’ post-treatment quality of life (QoL), sexual activity, self-esteem, fatigue and fear of disease recurrence. (2) Methods: A cross-sectional study was conducted at the Clinic of Urology, University Clinical Centre of Serbia, and included 31 PC patients. Data were collected by means of a questionnaire. (3) Results: The average score on the Global health status scale was 67.2 out of 100 (ranging from 16.7 to 100), and the SD was 22.5. Hierarchical linear regression analysis showed that demographic characteristics, Hospital Anxiety and Depression scale (HADS) anxiety and depression scores, total Multidimensional Fatigue Inventory, Fear of cancer recurrence and Rosenberg scores and erectile function score explained a total of 78.2% of the variance in the global health status/QoL scale of PC patients. (4) Conclusions: Efforts should be made not only to increase the survival of PC patients after surgical treatment but also to enable the best possible level of QoL in the post-operative period. Full article
(This article belongs to the Special Issue Urological Cancer Care—Improving Patient Outcomes)
11 pages, 533 KiB  
Article
New Hydronephrosis in the Native Kidney Is Associated with the Development of De Novo Urinary Bladder Urothelial Carcinoma in Patients with Post-Kidney Transplantation
by Cheng-Ju Ho, Yu-Hui Huang, Tzuo-Yi Hsieh, Min-Hsin Yang, Shao-Chuan Wang, Wen-Jung Chen, Wen-Wei Sung and Sung-Lang Chen
Healthcare 2023, 11(9), 1209; https://doi.org/10.3390/healthcare11091209 - 23 Apr 2023
Viewed by 1015
Abstract
Increased malignancy after kidney transplantation (KT) is by far the most troublesome issue. Among these malignancies, urothelial carcinoma (UC) incidence is uniquely high in Taiwan. We want to know whether routine sonography to detect native hydronephrosis is associated with the development of de [...] Read more.
Increased malignancy after kidney transplantation (KT) is by far the most troublesome issue. Among these malignancies, urothelial carcinoma (UC) incidence is uniquely high in Taiwan. We want to know whether routine sonography to detect native hydronephrosis is associated with the development of de novo urinary bladder urothelial carcinoma (UBUC) in post-KT recipients. From 2003 to 2018, we retrospectively analyzed 1005 KT patients, 58 of whom were subsequently diagnosed with UBUC. The association between new native hydronephrosis and post-KT UBUC was analyzed with univariate and multivariate logistic regression analyses and a Kaplan–Meier plot. We excluded cases of people who had upper urinary tract urothelial carcinoma (UTUC) and were diagnosed prior to UBUC. There were 612 males (60.9%) and 393 females (39.1%), with a mean age of 48.2 ± 12.0 years old at KT. The mean follow-up period was 118.6 ± 70.2 months, and the diagnosis of UBUC from KT to UBUC was 7.0 ± 5.1 years. New native kidney hydronephrosis occurred more frequently in the UBUC group (56.4% versus 6.4%, p < 0.001) than the non-UBUC group. Multivariate analysis disclosed that native hydronephrosis is the only statistically significant factor for UBUC, with an odds ratio of 16.03 (95% CI, 8.66–29.68; p < 0.001). UBUC in post-KT patients with native hydronephrosis also showed a tendency toward multifocal lesions upon presentation (47.8%). Post-KT UBUC is characterized by pathologically aggressive and multiple foci lesions. Native kidney hydronephrosis may be a deciding factor of post-KT UBUC. Full article
(This article belongs to the Special Issue Urological Cancer Care—Improving Patient Outcomes)
►▼ Show Figures

Figure 1

13 pages, 1420 KiB  
Article
A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania
by Vlad Barbos, Bogdan Feciche, Felix Bratosin, Iulia Bogdan, Rodica Anamaria Negrean, Silviu Latcu, Alexei Croitor, Vlad Dema, Razvan Bardan and Alin Adrian Cumpanas
Healthcare 2023, 11(6), 812; https://doi.org/10.3390/healthcare11060812 - 09 Mar 2023
Cited by 3 | Viewed by 1362
Abstract
The COVID-19 pandemic caused major changes in the healthcare sector due to adaptations required to hospitalize and treat an impressive number of patients. This retrospective study intended to collect reliable information on urothelial cancer patients in Romania. The primary objective was to compare [...] Read more.
The COVID-19 pandemic caused major changes in the healthcare sector due to adaptations required to hospitalize and treat an impressive number of patients. This retrospective study intended to collect reliable information on urothelial cancer patients in Romania. The primary objective was to compare the pre-pandemic and pandemic periods to observe the differences that occurred in the management of patients with urothelial carcinoma. The secondary objective was to determine the risk factors for urothelial cancer progression in the study cohort correlated with the COVID-19 pandemic. All patients that were diagnosed and treated at our clinic with a diagnosis of urothelial carcinoma (transitional cell carcinoma) during 2019–2021 were included in the current study. A total of 1122 eligible unique cases were identified during the study period. The number of patients who underwent intervention in the pre-pandemic year was 421, followed by a 22.6% decrease in 2020 to 326 cases and a 13.1% increase in 2021 to 375 cases. The proportion of muscle-invasive bladder cancer (MIBC) cases was significantly higher during the pandemic years, from 30.5% MIBC cases in 2019 to 37.4% in 2020 and 39.4% in 2021, suggesting a delay in presentations during the pandemic. Stage III and IV (TNM) cases were significantly more frequent, even though approximately 40% of all patients were operated on in stage I. The number of cystectomies increased significantly, from 5.2% in 2019 and 4.3% in 2020 to 10.1% in 2021, while the number of elective surgeries decreased, although no significant difference was observed regarding the in-hospital mortality and disease progression at six months. Patients with stage III and IV at presentation had the highest likelihood of disease progression at six months (HR = 5.61). Distant invasion was the second highest risk factor (HR = 5.13), followed by MIBC type (HR = 2.49). Nevertheless, the duration of hospitalization and year of diagnosis during the COVID-19 pandemic were not significant risk factors for cancer progression at six months. It can be concluded that there was a significant delay in patient presentations in 2020, and we advocate for increased public health awareness for urothelial cancer and increased attention toward the screening and management of these patients in the following years. Full article
(This article belongs to the Special Issue Urological Cancer Care—Improving Patient Outcomes)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop